Navigation Links
SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
Date:5/6/2008

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) will announce financial results for the first quarter of 2008 on Tuesday May 13, 2008. The announcement will be followed by a live conference call and webcast at 8:00 a.m. Pacific Time on that same day. Mike Grey, President and Chief Executive Officer, Stephen Burley, Chief Scientific Officer and Todd Myers, Chief Financial Officer, will host the conference call to discuss financial results and business highlights.

A scientific backgrounder is available at http://www.sgxpharma.com/pipeline/posterspubs.php

Interested participants and investors may access the teleconference call by dialing 866-825-1709 (U.S./Canada) or 617-213-8060 (international), participant code 72662683. A telephonic replay will be available for seven days following the call. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international), participant code 83759897.

A live webcast will be available under the investor relations section of the Company's website at http://www.sgxpharma.com. Replays of the webcast will be available for 30 days following the event. Please connect to the Company's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About SGX Pharmaceuticals

SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio
'/>"/>

SOURCE SGX Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, a ... editorials addressing developments and pathways related to oncological ... article exploring the role of follicle-stimulating hormone (FSH) ... prostate cancer. , The article references seminal ... there could be a connection to prostate cancer ...
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
(Date:12/19/2014)... 2014 Naurex Inc., a biopharmaceutical company leveraging ... of the central nervous system, today announced that ... will present at the 33 rd annual J.P. ... at 3:00 p.m. PST on Tuesday, January 13, 2015, ... Francisco, Calif. About Naurex ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today ... of Cardiology Foundation and the American Heart,Association and ... that,"ranolazine may be safely administered for symptom relief ... indicated for the,treatment of chronic angina in patients ...
... Million ... profit increases 18% to $2.2 Million for Q2 of 2007 versus $1.9 ... Million for Q2 of 2006,-- Announces LOI to Restructure $11.5 Million of Debt to Equity and Acquire ... Remaining 49% of Erye, BEIJING, Aug. 15 /Xinhua-PRNewswire-FirstCall/ -- China,Biopharmaceuticals Holdings, Inc. ...
... ANNAPOLIS, Md., Aug. 13 PharmAthene, Inc.,(Amex: ... medical,countermeasures against biological and chemical threats, announced today,that ... Court to,affirm the validity of the merger between ... the Court of Chancery will determine that the ...
Cached Biology Technology:Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI) 2China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results 2China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results 3China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results 4China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results 5China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results 6China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results 7China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results 8China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results 9China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results 10Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court 2
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... dioxide levels will reduce the density of coral skeletons, making ... a new study of corals growing where submarine springs naturally ... by researchers at the University of California, Santa Cruz, and ... Sciences ( PNAS ), is the first to show ...
... excess energy through the production of hydrogen. Biologists at the Ruhr-Universitt ... oxygen. For this, they need the messenger molecule nitric oxide and ... of humans. With colleagues at the UC Los Angeles, the Bochum ... an old protein in a new look In ...
... Yehia, M.D., M.P.P., M.S.H.P., Department of Medicine at the ... Health Equity Research and Promotion (CHERP), has received a ... and leadership in the field of HIV health services ... health outcomes of individuals living with chronic viral diseases ...
Cached Biology News:Submarine springs reveal how coral reefs respond to ocean acidification 2When green algae run out of air 2The American Society for Microbiology honors Baligh Yehia 2
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... Rabbit polyclonal to Taura Syndrome ... for all tested applications). ... Synthetic peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN ... corresponding to N terminal amino ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Biology Products: